Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agere Pharmaceuticals has expanded its cGMP spray dry manufacturing capabilities to support its clients entering Phase IIb clinical trials for cGMP manufacturing.
Subscribe to our email newsletter
The new service will help its clients, entering for formulation development, to enhance oral bioavailability of their BCS II and IV compounds.
Several pharmaceutical companies face solubility challenges with active pharmaceutical ingredients, according to the company.
Agere president and CEO Marshall Crew said the company has extended its cGMP spray drying capabilities in response to its clients’ requests to continue as they enter Phase IIb clinical trials.
"This is a natural progression for us, as expanding services delivers efficiencies to our clients," Crew added.